<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26193302</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.</ArticleTitle><Pagination><StartPage>3891</StartPage><EndPage>3909</EndPage><MedlinePgn>3891-909</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/v7072803</ELocationID><Abstract><AbstractText>Coxsackievirus A16 (CA16) and enterovirus 71 (EV71), both of which can cause hand, foot and mouth disease (HFMD), are responsible for large epidemics in Asian and Pacific areas. Although inactivated EV71 vaccines have completed testing in phase III clinical trials in Mainland China, CA16 vaccines are still under development. A Vero cell-based inactivated CA16 vaccine was developed by our group. Screening identified a CA16 vaccine strain (CC024) isolated from HFMD patients, which had broad cross-protective abilities and satisfied all requirements for vaccine production. Identification of the biological characteristics showed that the CA16CC024 strain had the highest titer (107.5 CCID50/mL) in Vero cells, which would benefit the development of an EV71/CA16 divalent vaccine. A potential vaccine manufacturing process was established, including the selection of optimal time for virus harvesting, membrane for diafiltration and concentration, gel-filtration chromatography for the down-stream virus purification and virus inactivation method. Altogether, the analyses suggested that the CC-16, a limiting dilution clone of the CC024 strain, with good genetic stability, high titer and broad-spectrum immunogenicity, would be the best candidate strain for a CA16 inactivated vaccine. Therefore, our study provides valuable information for the development of a Vero cell-based CA16 or EV71-CA16 divalent inactivated vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jingliang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China. jingliang_li1030@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guanchen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China. fry88614822@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China. liuxin87529524@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jiaxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China. yjx19861122@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Junliang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China. cjlcc2009@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenyan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China. zhangwenyan@jlu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xiao-Fang</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China. xyu2@jhu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA. xyu2@jhu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">inactivated vaccine</Keyword><Keyword MajorTopicYN="N">vaccine candidate strain</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26193302</ArticleId><ArticleId IdType="pmc">PMC4517132</ArticleId><ArticleId IdType="doi">10.3390/v7072803</ArticleId><ArticleId IdType="pii">v7072803</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 2002;26:91&#x2013;107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Liang Z.L., Meng F.Y., Zeng Y., Mao Q.Y., Chu K., Song X.F., Yao X., Li J.X., Ji H., et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS ONE. 2012;7:e37206. doi: 10.1371/journal.pone.0037206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037206</ArticleId><ArticleId IdType="pmc">PMC3360679</ArticleId><ArticleId IdType="pubmed">22662137</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Liang Z.L., Li X.L., Ge H.M., Meng F.Y., Mao Q.Y., Zhang Y.T., Hu Y.M., Zhang Z.Y., Li J.X., et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381:1037&#x2013;1045. doi: 10.1016/S0140-6736(12)61764-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Tan X.J., Wang H.Y., Yan D.M., Zhu S.L., Wang D.Y., Ji F., Wang X.J., Gao Y.J., Chen L., et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J. Clin. Virol. 2009;44:262&#x2013;267. doi: 10.1016/j.jcv.2009.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.02.002</ArticleId><ArticleId IdType="pubmed">19269888</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., Jin Q., He Y., Li L., Hou Y. The complete genome of Enterovirus 71 China strain. Sci. China Ser. C Life Sci. 2001;44:178&#x2013;183. doi: 10.1007/BF02879323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02879323</ArticleId><ArticleId IdType="pubmed">18726435</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.C., Chang H.L., Yan T.R., Cheng Y.T., Chen K.T. An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am. J. Trop. Med. Hyg. 2007;77:188&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620652</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto K., Sanefuji M., Kusuhara K., Nishimura Y., Shimizu H., Kira R., Torisu H., Hara T. Rhombencephalitis and coxsackievirus A16. Emerg. Infect. Dis. 2009;15:1689&#x2013;1691. doi: 10.3201/eid1510.090594.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1510.090594</ArticleId><ArticleId IdType="pmc">PMC2866411</ArticleId><ArticleId IdType="pubmed">19861078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang L.W., Koh B.K., Chan K.P., Chua L.T., James L., Goh K.T. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001&#x2013;2007. Ann. Acad. Med. Singapore. 2009;38:106&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">19271036</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson C.R., Doane F.W., Rhodes A.J. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; isolation of group A Coxsackie virus. Can. Med. Assoc. J. 1958;79:615&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1830188</ArticleId><ArticleId IdType="pubmed">13585281</ArticleId></ArticleIdList></Reference><Reference><Citation>Urquhart G.E. A survey of coxsackie A16 virus antibodies in human sera. J. Hyg. 1984;93:205&#x2013;212. doi: 10.1017/S002217240006472X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S002217240006472X</ArticleId><ArticleId IdType="pmc">PMC2129431</ArticleId><ArticleId IdType="pubmed">6094661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.Y., Lu F.L., Wu M.H., Lee C.Y., Huang L.M. Fatal coxsackievirus A16 infection. Pediatr. Infect. Dis. J. 2004;23:275&#x2013;276. doi: 10.1097/01.inf.0000115950.63906.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000115950.63906.78</ArticleId><ArticleId IdType="pubmed">15014311</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright H.T., Jr., Landing B.H., Lennette E.H., Mc A.R. Fatal infection in an infant associated with Coxsackie virus group A, type 16. N. Engl. J. Med. 1963;268:1041&#x2013;1044. doi: 10.1056/NEJM196305092681904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM196305092681904</ArticleId><ArticleId IdType="pubmed">14001956</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip C.C., Lau S.K., Zhou B., Zhang M.X., Tsoi H.W., Chan K.H., Chen X.C., Woo P.C., Yuen K.Y. Emergence of enterovirus 71 &#x201c;double-recombinant&#x201d; strains belonging to a novel genotype D originating from southern China: First evidence for combination of intratypic and intertypic recombination events in EV71. Arch. Virol. 2010;155:1413&#x2013;1424. doi: 10.1007/s00705-010-0722-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-010-0722-0</ArticleId><ArticleId IdType="pmc">PMC7087135</ArticleId><ArticleId IdType="pubmed">20549263</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Zhang Y., Yang E., Liu L., Che Y., Wang J., Zhao H., Tang D., Dong C., Yang L., et al. The effect of enterovirus 71 immunization on neuropathogenesis and protein expression profiles in the thalamus of infected rhesus neonates. Virology. 2012;432:417&#x2013;426. doi: 10.1016/j.virol.2012.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.06.026</ArticleId><ArticleId IdType="pubmed">22819834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhu Z., Yang W., Ren J., Tan X., Wang Y., Mao N., Xu S., Zhu S., Cui A., et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol. J. 2010;7 doi: 10.1186/1743-422X-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z., Mao Q., Gao F., Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front. Med. 2013;7:111&#x2013;121. doi: 10.1007/s11684-012-0237-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-012-0237-z</ArticleId><ArticleId IdType="pubmed">23247645</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H.J., Song J.H., Park K.S., Baek S.H. In vitro anti-enterovirus 71 activity of gallic acid from Woodfordia fruticosa flowers. Lett. Appl. Microbiol. 2010;50:438&#x2013;440. doi: 10.1111/j.1472-765X.2010.02805.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1472-765X.2010.02805.x</ArticleId><ArticleId IdType="pubmed">20149083</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z., Wang J. EV71 vaccine, an invaluable gift for children. Clin. Transl. Immunol. 2014;3 doi: 10.1038/cti.2014.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cti.2014.24</ArticleId><ArticleId IdType="pmc">PMC4237031</ArticleId><ArticleId IdType="pubmed">25505956</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Yan K., Feng Y., Huang X., Ku Z., Cai Y., Liu F., Shi J., Huang Z. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012;30:6642&#x2013;6648. doi: 10.1016/j.vaccine.2012.08.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.08.071</ArticleId><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Li N., Yu X., Yao X., Li F., Lu F., Zhuang H., Liang Z., Wang J. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch. Virol. 2012;157:37&#x2013;41. doi: 10.1007/s00705-011-1136-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1136-3</ArticleId><ArticleId IdType="pubmed">21984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Hsieh S.Y., Liu C.C., Chou A.H., Chang J.Y., Wu S.C., Liu S.J., Chow Y.H., Su I.J., Klein M. Production of EV71 vaccine candidates. Hum. Vaccin. Immunother. 2012;8:1775&#x2013;1783. doi: 10.4161/hv.21739.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21739</ArticleId><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Chang J., Liu X., Yang J., Guo H., Wei W., Zhang W., Yu X.F. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J. Gen. Virol. 2014;95:1083&#x2013;1093. doi: 10.1099/vir.0.063560-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.063560-0</ArticleId><ArticleId IdType="pmc">PMC3983757</ArticleId><ArticleId IdType="pubmed">24496826</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L.J., Muench H. A simple method of estimating fifity percent endpoints. Am. J. Hyg. 1938;27:493&#x2013;497.</Citation></Reference><Reference><Citation>Wei W., Guo H., Li J., Ren S., Wei Z., Bao W., Hu X., Zhao K., Zhang W., Zhou Y., et al. Circulating HFMD-associated coxsackievirus A16 is genetically and phenotypically distinct from the prototype CV-A16. PLoS ONE. 2014;9:e94746. doi: 10.1371/journal.pone.0094746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094746</ArticleId><ArticleId IdType="pmc">PMC3988102</ArticleId><ArticleId IdType="pubmed">24736564</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry S., Fry E., Blakemore W., Abu-Ghazaleh R., Jackson T., King A., Lea S., Newman J., Stuart D. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: The structure of empty capsids of foot-and-mouth disease virus. J. Virol. 1997;71:9743&#x2013;9752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230284</ArticleId><ArticleId IdType="pubmed">9371640</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Guo M.S., Lin F.H., Hsiao K.N., Weng S.Y., Chou A.H., Wang J.R., Hsieh S.Y., Su I.J., Liu C.C. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS ONE. 2012;7:e49973. doi: 10.1371/journal.pone.0049973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049973</ArticleId><ArticleId IdType="pmc">PMC3511423</ArticleId><ArticleId IdType="pubmed">23226233</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom N., Hansen J., Blaas D., Brunak S. Cleavage site analysis in picornaviral polyproteins: Discovering cellular targets by neural networks. Protein Sci. 1996;5:2203&#x2013;2216. doi: 10.1002/pro.5560051107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.5560051107</ArticleId><ArticleId IdType="pmc">PMC2143287</ArticleId><ArticleId IdType="pubmed">8931139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20:895&#x2013;904. doi: 10.1016/S0264-410X(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Chou A.H., Lien S.P., Lin H.Y., Liu S.J., Chang J.Y., Guo M.S., Chow Y.H., Yang W.S., Chang K.H., et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29:4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J.Y., Chang C.P., Tsai H.H., Lee C.D., Lian W.C., Ih Jen S., Sai I.H., Liu C.C., Chou A.H., Lu Y.J., et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine. 2012;30:703&#x2013;711. doi: 10.1016/j.vaccine.2011.11.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.11.087</ArticleId><ArticleId IdType="pubmed">22142585</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara A., Tagaya I., Yoneyama T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology. 1978;9:60&#x2013;63. doi: 10.1159/000148922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000148922</ArticleId><ArticleId IdType="pubmed">202573</ArticleId></ArticleIdList></Reference><Reference><Citation>Iakovenko M.L., Korotkova E.A. Evolution of vaccine poliovirus strains. Vopr. Virusol. 2008;53:45&#x2013;48. following back cover.</Citation><ArticleIdList><ArticleId IdType="pubmed">18590137</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G., Alonso S., Chow V.T., Poh C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes. Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlecken D.H., Pelgrim R.P., Ruminski S., Bakker W.A., van der Pol L.A. Comparison of initial feasibility of host cell lines for viral vaccine production. J. Virol. Methods. 2013;193:28&#x2013;41. doi: 10.1016/j.jviromet.2013.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2013.04.020</ArticleId><ArticleId IdType="pubmed">23684847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalbfuss B., Wolff M., Morenweiser R., Reichl U. Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Biotechnol. Bioeng. 2007;96:932&#x2013;944. doi: 10.1002/bit.21109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.21109</ArticleId><ArticleId IdType="pmc">PMC7161795</ArticleId><ArticleId IdType="pubmed">16937411</ArticleId></ArticleIdList></Reference><Reference><Citation>Govorkova E.A., Murti G., Meignier B., de Taisne C., Webster R.G. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J. Virol. 1996;70:5519&#x2013;5524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190510</ArticleId><ArticleId IdType="pubmed">8764064</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.W., Lee Y.P., Wang Y.F., Yu C.K. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine. 2011;29:2772&#x2013;2776. doi: 10.1016/j.vaccine.2011.01.094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.01.094</ArticleId><ArticleId IdType="pubmed">21315698</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>